NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis
S Tsimikas, S Fazio, KC Ferdinand… - Journal of the American …, 2018 - jacc.org
Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
PCSK9: from basic science discoveries to clinical trials
Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now
common parlance among scientists and clinicians interested in prevention and treatment of …
common parlance among scientists and clinicians interested in prevention and treatment of …
Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial
ML O'Donoghue, S Fazio, RP Giugliano, ESG Stroes… - Circulation, 2019 - ahajournals.org
Background: Lipoprotein (a)[Lp (a)] may play a causal role in atherosclerosis. PCSK9
(proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce …
(proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce …
Inhibiting PCSK9—biology beyond LDL control
Clinical trials have unequivocally shown that inhibition of proprotein convertase
subtilisin/kexin type 9 (PCSK9) efficaciously and safely prevents cardiovascular events by …
subtilisin/kexin type 9 (PCSK9) efficaciously and safely prevents cardiovascular events by …
[HTML][HTML] The PCSK9 revolution: current status, controversies, and future directions
Abstract Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has revolutionized our
understanding of cholesterol homeostasis and added to our arsenal against atherosclerotic …
understanding of cholesterol homeostasis and added to our arsenal against atherosclerotic …
[HTML][HTML] Modern approaches to lower lipoprotein (a) concentrations and consequences for cardiovascular diseases
Lipoprotein (a)(Lp (a)) is a low density lipoprotein particle that is associated with poor
cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro …
cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro …
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors
Abstract Aims Lipoprotein (a)[Lp (a)] is a lipoprotein species causatively associated with
atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp (a), but this reduction …
atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp (a), but this reduction …
Relationship between low‐density lipoprotein cholesterol and lipoprotein (a) lowering in response to PCSK9 inhibition with evolocumab
Background Beyond their potent LDL (low‐density lipoprotein) cholesterol (LDL‐C)–
lowering efficacy (50–60%), PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors …
lowering efficacy (50–60%), PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors …
Lipoprotein (a) and atherosclerotic cardiovascular disease: current understanding and future perspectives
MF Wu, KZ Xu, YG Guo, J Yu, Y Wu, LM Lin - Cardiovascular Drugs and …, 2019 - Springer
Purpose To review current knowledge of elevated lipoprotein (a)[Lp (a)] levels in relation to
atherosclerotic cardiovascular disease (ASCVD) and discuss their potential use as …
atherosclerotic cardiovascular disease (ASCVD) and discuss their potential use as …
[HTML][HTML] Sex X Time Interactions in Lp (a) and LDL-C Response to Evolocumab
The aim of this study was to evaluate whether there were significant sex x time interactions
in lipoprotein (a)(Lp (a)) and low-density lipoprotein cholesterol (LDL-C) response to …
in lipoprotein (a)(Lp (a)) and low-density lipoprotein cholesterol (LDL-C) response to …